GlassScriptPhysician profile
Terrie Branson
NPI 1104367168
$4,933.68
in general payments reported to CMS, 2019-2025
26 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $894 · 2023: $1,228 · 2024: $1,354 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,777 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,776.50 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,326.17 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $654.65 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $627.22 | 2021-2025 | Verquvo |
| Pfizer INC. | $409.16 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $369.62 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.22 | 2021-2025 | Jardiance |
| Medtronic, INC. | $156.23 | 2022-2025 | Azure Xt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $129.79 | 2021-2024 | Xarelto |
| Amgen INC. | $124.36 | 2022-2024 | Repatha |
| Edwards Lifesciences Corporation | $120.61 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lexicon Pharmaceuticals, INC. | $109.53 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $99.51 | 2024-2025 | Nexletol |
| Philips North America LLC | $99.47 | 2023-2024 | (Ck4) Mcot |
| Sanofi-Aventis U.S. LLC | $96.04 | 2021-2024 | |
| Scpharmaceuticals INC. | $65.34 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $61.46 | 2023-2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $33.26 | 2023 | Farxiga |
| Novo Nordisk INC | $27.34 | 2025 | Ozempic |
| Astellas Pharma US INC | $19.72 | 2022 | |
| Abbott Laboratories | $18.77 | 2023 | Assurity |
| Boston Scientific Corporation | $18.42 | 2021 | |
| Agepha Pharma Fz LLC | $16.37 | 2024 | Lodoco |
| Kiniksa Pharmaceuticals, LTD. | $16.07 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.48 | 2023 | Edarbyclor |
| Vifor Pharma, INC. | $13.92 | 2021 | |
| Lantheus Medical Imaging, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrie Branson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.